featured
Lower Cardiorenal Risk With Sodium–Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients Without Cardiovascular and Renal Diseases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lower Cardiorenal Risk With Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients Without Cardiovascular and Renal Diseases: A Large Multinational Observational Study
Diabetes Obes Metab 2020 Sep 07;[EPub Ahead of Print], KI Birkeland, J Bodegard, A Banerjee, DJ Kim, A Norhammar, JW Eriksson, M Thuresson, S Okami, KH Ha, N Kossack, JB Mamza, R Zhang, T Yajima, I Komuro, T KadowakiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.